

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

CIN: L24232MH2007PLC169354;

Tel: +91-22-2498 1650; Fax: +91-22-2497 0127

E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com



EXTRACT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2018

(Rs. in Lakhs)				
Particulars	Quarter ended		Year ended	
	March 31, 2018 (Audited) Refer Note 2	March 31, 2017 (Unaudited) Refer Note 2	March 31, 2018 (Audited)	March 31, 2017 (Audited)
1 Total Income from Operations	8,346	7,441	34,714	30,681
2 Net Profit for the period (before tax, exceptional and extraordinary items)	439	126	2,036	1,454
3 Net Profit for the period before tax (after exceptional and extraordinary items)	439	126	2,036	2,346
4 Net Profit for the period after tax (after Exceptional and Extraordinary items)	125	22	1,345	2,101
5 Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	180	28	1,331	2,038
6 Paid-up equity share capital (Face Value Rs.8/- each)	1,323	1,323	1,323	1,323
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the current year and previous year	-	-	14,152	13,378
8 Earnings Per Share (Rs.8/- each) - (from continuing and discontinued operations)				
Basic (in Rs.):	0.76	0.13	8.13	12.70
Diluted (in Rs.):	0.76	0.13	8.13	12.70

Note:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 2, 2018.
- The figures for the quarter ended March 31, 2018 are the balancing figures between the audited financial results for the year ended March 31, 2018 and the published unaudited financial results for the nine months ended December 31, 2017.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- On April 1, 2017 the Company has adopted the Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from April 1, 2016. Accordingly the financial results for the quarter and year ended March 31, 2018 have been prepared in accordance with Ind AS and other accounting principles generally accepted in India and the results for the comparative quarter and year ended March 31, 2017 have been restated in accordance with Ind AS.
- Reconciliation of results between amounts previously reported (referred to as previous GAAP) and Ind AS is presented below:

(Rs. in Lakhs)

Particulars	Quarter ended 31-Mar-17	Year ended 31-Mar-17
Profit for the period as per previous GAAP	(21)	2,046
Re-measurement of revenue (a)	33	(13)
Re-measurement of Employee Benefit (b)	22	91
Provision for Expected Credit Loss (c)	-	(11)
Borrowing Cost (d)	11	11
Tax impact of the above	(24)	(24)
Other Comprehensive Income Net of Tax	21	2,100
Re-measurement of Employee Benefit Net of tax	(15)	(63)
Total Comprehensive Income for the period	6	2,037

Profit reconciliation Notes

- Provision for sales return has been made under Ind AS as per past trend of sales return to sales.
 - The remeasurement cost arising primarily due to changes in actuarial assumptions have been recognised in Other Comprehensive Income under Ind AS as compared to Statement of Profit or Loss under previous GAAP.
 - The Company has applied expected credit loss (ECL) model for measurement & recognition of impairment loss on trade and other receivables as per the provisions of Ind AS 109.
 - Under the IGAAP, the transaction cost was charged to Profit and loss Account which under IndAS it is amortised over the period of loan.
- The Board of Directors has recommended a normal dividend of Rs. 2.40/- per share of Rs 8/- each (30%) for the year ended March 31, 2018, subject to the approval of members at the ensuing Annual General Meeting.
 - The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on Stock Exchange websites viz. (www.nseindia.com and www.bseindia.com) and on Company's website (www.rpglifesciences.com).

For RPG Life Sciences Limited

CT. Renganathan
Managing Director
DIN-02158397

Place : Mumbai
Date : May 2, 2018




RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

CIN: L24232MH2007PLC169354;

Tel: +91-22-2498 1650; Fax: +91-22-2497 0127

E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com



EXTRACT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2018

(Rs. in Lakhs)

Particulars	Quarter ended		Year ended	
	March 31, 2018	March 31, 2017	March 31, 2018	March 31, 2017
	(Audited) Refer Note 2	(Unaudited) Refer Note 2	(Audited)	(Audited)
1 Total Income from Operations	8,346	7,441	34,714	30,681
2 Net Profit for the period (before tax, exceptional and extraordinary items)	439	126	2,036	1,454
3 Net Profit for the period before tax (after exceptional and extraordinary items)	439	126	2,036	2,346
4 Net Profit for the period after tax (after Exceptional and Extraordinary items)	125	22	1,345	2,101
5 Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	180	28	1,331	2,038
6 Paid-up equity share capital (Face Value Rs.8/- each)	1,323	1,323	1,323	1,323
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the current year and previous year	-	-	14,152	13,378
8 Earnings Per Share (Rs.8/- each) - (from continuing and discontinued operations)	0.76	0.13	8.13	12.70
Basic (in Rs.):	0.76	0.13	8.13	12.70
Diluted (in Rs.):	0.76	0.13	8.13	12.70

Note:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 2, 2018.
- The figures for the quarter ended March 31, 2018 are the balancing figures between the audited financial results for the year ended March 31, 2018 and the published unaudited financial results for the nine months ended December 31, 2017.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- On April 1, 2017 the Company has adopted the Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from April 1, 2016. Accordingly the financial results for the quarter and year ended March 31, 2018 have been prepared in accordance with Ind AS and other accounting principles generally accepted in India and the results for the comparative quarter and year ended March 31, 2017 have been restated in accordance with Ind AS.
- Reconciliation of results between amounts previously reported (referred to as previous GAAP) and Ind AS is presented below:

(Rs. in Lakhs)

Particulars	Quarter ended 31-Mar-17	Year ended 31-Mar-17
Profit for the period as per previous GAAP	(21)	2,046
Re-measurement of revenue (a)	33	(13)
Re-measurement of Employee Benefit (b)	22	91
Provision for Expected Credit Loss (c)	-	(11)
Borrowing Cost (d)	11	11
Tax impact of the above	(24)	(24)
Other Comprehensive Income Net of Tax	21	2,100
Re-measurement of Employee Benefit Net of tax	(15)	(63)
Total Comprehensive Income for the period	6	2,037

Profit reconciliation Notes

- Provision for sales return has been made under Ind AS as per past trend of sales return to sales.
 - The remeasurement cost arising primarily due to changes in actuarial assumptions have been recognised in Other Comprehensive Income under Ind AS as compared to Statement of Profit or Loss under previous GAAP.
 - The Company has applied expected credit loss (ECL) model for measurement & recognition of impairment loss on trade and other receivables as per the provisions of Ind AS 109.
 - Under the IGAAP, the transaction cost was charged to Profit and loss Account which under IndAS it is amortised over the period of loan.
- The Board of Directors has recommended a normal dividend of Rs. 2.40/- per share of Rs 8/- each. (30%) for the year ended March 31, 2018, subject to the approval of members at the ensuing Annual General Meeting.
 - The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on Stock Exchange websites viz. (www.nseindia.com and www.bseindia.com) and on Company's website (www.rpglifesciences.com).

For RPG Life Sciences Limited

CT. Renganathan
Managing Director
DIN-02158397

Place : Mumbai
Date : May 2, 2018

